Delcath Systems (DCTH) Competitors $11.12 +0.71 (+6.82%) Closing price 04:00 PM EasternExtended Trading$11.06 -0.06 (-0.55%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DCTH vs. NVCR, SSII, CDRE, BLFS, ESTA, PLSE, MDXG, INMD, IRMD, and KMTSShould you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include NovoCure (NVCR), SS Innovations International (SSII), Cadre (CDRE), BioLife Solutions (BLFS), Establishment Labs (ESTA), Pulse Biosciences (PLSE), MiMedx Group (MDXG), InMode (INMD), iRadimed (IRMD), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry. Delcath Systems vs. Its Competitors NovoCure SS Innovations International Cadre BioLife Solutions Establishment Labs Pulse Biosciences MiMedx Group InMode iRadimed Kestra Medical Technologies Delcath Systems (NASDAQ:DCTH) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Is DCTH or NVCR more profitable? Delcath Systems has a net margin of 3.18% compared to NovoCure's net margin of -27.13%. Delcath Systems' return on equity of 6.91% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets Delcath Systems3.18% 6.91% 5.80% NovoCure -27.13%-47.74%-13.79% Do analysts rate DCTH or NVCR? Delcath Systems presently has a consensus target price of $24.50, suggesting a potential upside of 120.32%. NovoCure has a consensus target price of $28.79, suggesting a potential upside of 131.58%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than Delcath Systems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00NovoCure 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Do institutionals and insiders believe in DCTH or NVCR? 61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 17.4% of Delcath Systems shares are held by company insiders. Comparatively, 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, DCTH or NVCR? Delcath Systems has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Does the media refer more to DCTH or NVCR? In the previous week, NovoCure had 3 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for NovoCure and 2 mentions for Delcath Systems. NovoCure's average media sentiment score of 0.62 beat Delcath Systems' score of 0.62 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, DCTH or NVCR? Delcath Systems has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDelcath Systems$37.21M10.45-$26.39M$0.05222.40NovoCure$605.22M2.30-$168.63M-$1.56-7.97 SummaryDelcath Systems beats NovoCure on 10 of the 15 factors compared between the two stocks. Get Delcath Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DCTH vs. The Competition Export to ExcelMetricDelcath SystemsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$364.15M$6.88B$5.76B$9.59BDividend YieldN/A1.31%4.41%4.09%P/E Ratio222.4027.4531.1026.05Price / Sales10.4575.20470.24120.75Price / CashN/A21.3437.7358.48Price / Book3.716.889.536.61Net Income-$26.39M$176.42M$3.26B$265.56M7 Day Performance7.34%0.58%2.11%1.98%1 Month Performance0.36%-0.45%5.12%1.33%1 Year Performance41.30%13.07%31.25%21.15% Delcath Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DCTHDelcath Systems2.6673 of 5 stars$11.12+6.8%$24.50+120.3%+30.6%$364.15M$37.21M222.4060Short Interest ↑NVCRNovoCure4.136 of 5 stars$12.09+3.1%$28.79+138.1%-31.9%$1.31B$605.22M-7.751,488News CoverageSSIISS Innovations InternationalN/A$6.55-2.1%N/AN/A$1.30B$20.65M0.004CDRECadre2.0185 of 5 stars$29.66+1.4%$31.50+6.2%-16.7%$1.19B$567.56M31.552,284BLFSBioLife Solutions2.5841 of 5 stars$24.50+0.7%$31.29+27.7%-2.5%$1.17B$82.25M-204.15440News CoverageInsider TradeESTAEstablishment Labs1.9601 of 5 stars$38.25-0.2%$55.80+45.9%-9.2%$1.11B$166.02M-12.541,018News CoveragePositive NewsAnalyst ForecastPLSEPulse Biosciences3.5376 of 5 stars$15.68-3.0%$22.00+40.3%-26.7%$1.09B$700K-14.93140MDXGMiMedx Group3.2713 of 5 stars$7.19+1.1%$12.00+66.9%+7.0%$1.05B$348.88M34.24870Positive NewsINMDInMode2.0176 of 5 stars$14.31-0.3%$18.04+26.1%-11.2%$907.05M$394.82M5.79480Positive NewsIRMDiRadimed4.6421 of 5 stars$70.11-0.4%$72.00+2.7%+56.9%$895.23M$73.24M43.28110KMTSKestra Medical TechnologiesN/A$16.09+0.2%$27.33+69.9%N/A$824.15M$59.81M0.00300Positive News Related Companies and Tools Related Companies NovoCure Competitors SS Innovations International Competitors Cadre Competitors BioLife Solutions Competitors Establishment Labs Competitors Pulse Biosciences Competitors MiMedx Group Competitors InMode Competitors iRadimed Competitors Kestra Medical Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DCTH) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access